Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

NCT01239134 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Interventions

BIOLOGICAL: TRX518

Sponsor

Leap Therapeutics, Inc.

Collaborators

[object Object]